\
&
Contact us
\
&
Contact us
The partnership aims to deliver key knowledge, services and products to significantly improve the control of animal infectious diseases and animal welfare in a coordinated way which will sustain animal production and protect public health. It involves laboratories, funding agencies and the private sector.
By 2030, programmes will be further aligned, the animal health and welfare research and innovation ecosystem will be stronger, improving preparedness and providing additional solutions to prevent, detect and respond to priority infectious animal diseases, fight antimicrobial resistance, and improve animal welfare.
The partnership will launch its second external co-funded research and innovation call "shaping the future of animal health and welfare" during the course of January 2026. The Call will aim to foster international collaboration and impactful research and innovation across Europe and will be supported by funding organisations across 19 countries. Proposals submitted under this Call must address animal welfare or prevention and control and spanning welfare assessment, humane transport and slaughter, disease prevention, resilience, therapeutics, and innovation. You can find more information about the call on this website.
Contact
Commission services: Jean-Charles Cavitte, Valerio Abbadessa
Partners: Ugent Nathalie Vanderheijden VLAIO Jef Willems
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
pascal.verheye@vlaio.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
